查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1813942

基於生物標記的免疫檢測市場規模、佔有率和趨勢分析報告：按樣本、產品、生物標記、疾病、最終用途、地區和細分市場預測，2025 年至 2033 年

Biomarker-based Immunoassays Market Size, Share & Trends Analysis Report By Sample (Blood, Saliva, Tissue, Urine) By Product (Reagents & Kits, Consumables), By Biomarker, By Diseases, By End-use, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

基於生物標記的免疫檢測市場摘要

預計 2024 年全球基於生物標記的免疫檢測市場價值將達到 51.5 億美元，到 2033 年將達到 83.3 億美元，2025 年至 2033 年的複合年成長率為 5.4%。

市場成長的動力來自於全球日益加重的慢性疾病負擔，例如癌症、心血管疾病和神經系統疾病，這些疾病需要精確和早期的診斷工具。

個人化醫療需求的日益成長，促使臨床醫生和製藥公司採用生物標記引導的策略，而免疫檢測在疾病檢測和治療監測中都發揮核心作用。監管部門對生物標記主導的疾病研發的支持，加上對伴隨診斷的日益依賴，已牢固確立了免疫檢測作為現代醫學必不可少的技術的地位。此外，公共和私人部門對轉化研究和臨床診斷的投資，正在加速其在醫院、研究實驗室和學術機構中的應用。

技術進步也在重塑市場格局。連接複用平台、高通量分析儀和新一代免疫檢測系統能夠同時檢測多種生物標記物，並提高靈敏度和特異性。人工智慧 (AI) 和機器學習 (ML) 融入基於生物標記的檢測，改善了數據解讀；基於液態切片的免疫檢測為腫瘤學和神經病學診斷提供了微創選擇。各公司也正在開發針對預測性和預後性生物標記的試劑和試劑套件，這些試劑和試劑盒在精準醫療中的價值日益凸顯。這些技術創新不僅提高了診斷準確性，還縮短了周轉時間，使生物標記免疫檢測更易於獲取，並更具臨床相關性。

目錄

第1章調查方法與範圍

第2章執行摘要

3. 全球基於生物標記的免疫檢測市場變數、趨勢和範圍

  • 市場體系展望
    • 母市場展望
    • 相關/輔助市場前景。
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 全球基於生物標記的免疫檢測市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

4. 全球基於生物標記的免疫檢測市場：樣本估計和趨勢分析

  • 細分儀表板
  • 全球基於生物標記的免疫檢測市場的樣本變異性分析
  • 全球基於生物標記的免疫檢測市場規模和趨勢分析（按樣本，2018-2030 年）
  • 血
  • 組織
  • 唾液
  • 尿

第5章全球基於生物標記的免疫檢測市場：產品估計和趨勢分析

  • 細分儀表板
  • 全球基於生物標記的免疫檢測市場的產品差異分析
  • 全球基於生物標記的免疫檢測市場規模和趨勢分析（按產品，2021-2033 年）
  • 耗材
  • 儀器/分析儀
  • 試劑和套件
  • 服務

6. 全球基於生物標記的免疫檢測市場：生物標記估計和趨勢分析

  • 細分儀表板
  • 全球基於生物標記的免疫檢測市場的生物標記變異分析
  • 全球基於生物標記的免疫檢測市場規模和趨勢分析（按生物標記，2021-2033 年）
  • 安全性和毒性生物標記
  • 療效和動態學生物標記
  • 預測和預後生物標記
  • 替代/探索性生物標記

7. 全球基於生物標記的免疫檢測市場：疾病評估與趨勢分析

  • 細分儀表板
  • 全球基於生物標記的免疫檢測市場疾病變異分析
    • 全球基於生物標記的免疫檢測市場規模和趨勢分析（按疾病，2021-2033 年）
  • 癌症
  • 心血管疾病
  • 神經系統疾病
  • 免疫疾病
  • 其他

8. 全球基於生物標記的免疫檢測市場：最終用途估計和趨勢分析

  • 細分儀表板
  • 全球基於生物標記的免疫檢測市場的最終用途變化分析
    • 全球基於生物標記的免疫檢測市場規模和趨勢分析（按最終用途）（2021-2033 年）
  • 醫院和診所
  • 診斷實驗室
  • 研究和學術機構
  • 其他

第9章基於生物標記的免疫檢測市場：區域估計和趨勢分析

  • 區域儀表板
  • 市場規模、預測趨勢分析，2021-2033年：
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第10章 競爭格局

  • 公司/競爭對手分類
  • 戰略地圖
  • 2024年公司市佔率分析
  • 主要認證提供者/計畫所有者列表
  • 公司簡介/上市公司
    • F. Hoffmann-La Roche AG
    • Abbott
    • Thermo Fisher Scientific Inc
    • Eurofins Scientific
    • QIAGEN
    • Bio-Rad Laboratories, Inc.
    • Siemens Healthineers AG
    • Merck KGaA
    • PerkinElmer Inc.
    • Agilent Technologies, Inc.
Product Code: GVR-4-68040-722-5

Biomarker-based Immunoassays Market Summary

The global biomarker-based immunoassays market size was valued at USD 5.15 billion in 2024 and is expected to reach USD 8.33 billion by 2033, growing at a CAGR of 5.4% from 2025 to 2033. The market growth is fueled by the rising global burden of chronic diseases such as cancer, cardiovascular disorders, and neurological conditions, which require precise and early diagnostic tools.

Increasing demand for personalized medicine has driven clinicians and pharmaceutical companies to adopt biomarker-guided strategies, where immunoassays play a central role in both disease detection and therapeutic monitoring. The increasing reliance on companion diagnostics, along with regulatory support for biomarker-driven disease development, has solidified immunoassays as an essential technology in modern healthcare. Additionally, public and private investments in translational research and clinical diagnostics have sped up adoption across hospitals, laboratories, and academic institutions.

Technological advancements are also reshaping the scope of the market, with multiplexing platforms, high-throughput analyzers, and next-generation immunoassay systems enabling the simultaneous detection of multiple biomarkers with enhanced sensitivity and specificity. The integration of artificial intelligence (AI) and machine learning (ML) into biomarker-based testing improves data interpretation, while liquid biopsy-based immunoassays offer less invasive options for oncology and neurology diagnostics. Companies are also developing reagents and kits tailored for predictive and prognostic biomarkers, which are increasingly valuable in precision medicine. These innovations not only enhance diagnostic accuracy but also reduce turnaround times, making biomarker immunoassays more accessible and clinically relevant.

Global Biomarker-based Immunoassays Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For the purpose of this report, Grand View Research has segmented the biomarker-based immunoassays market on the basis sample, product, biomarkers, diseases, end-use, and region:

  • Sample Outlook (Revenue, USD Million, 2021 - 2033)
  • Blood
  • Tissue
  • Urine
  • Saliva
  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Consumables
  • Instruments/ Analyzers
  • Reagent & Kits
  • Services
  • Biomarker Outlook (Revenue, USD Million, 2021 - 2033)
  • Safety & toxicity biomarkers
  • Efficacy & Pharmacodynamic Biomarkers
  • Predictive & Prognostic Biomarkers
  • Surrogate/Exploratory Biomarkers
  • Diseases Outlook (Revenue, USD Million, 2021 - 2033)
  • Cancer
  • Cardiovascular Diseases
  • Neurological Diseases
  • Immunological Diseases
  • Others
  • End-use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Research & Academic Institutes
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definitions
    • 1.2.1. Sample Segment
    • 1.2.2. Product Segment
    • 1.2.3. Biomarker Segment
    • 1.2.4. Diseases Segment
    • 1.2.5. End Use Segment
  • 1.3. Information analysis
    • 1.3.1. Market formulation & data visualization
  • 1.4. Data validation & publishing
  • 1.5. Information Procurement
    • 1.5.1. Primary Research
  • 1.6. Information or Data Analysis
  • 1.7. Market Formulation & Validation
  • 1.8. Market Biomarkerl
  • 1.9. Total Market: CAGR Calculation
  • 1.10. Objectives
    • 1.10.1. Objective 1
    • 1.10.2. Objective 2

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Insights Landscape

Chapter 3. Global Biomarker-Based Immunoassays Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising demand for precision medicine and personalized therapies
      • 3.2.1.2. Increasing prevalence of chronic and infectious diseases
      • 3.2.1.3. Technological advancements in immunoassay platforms
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High cost of advanced biomarker assays and platforms
  • 3.3. Global Biomarker-Based Immunoassays Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis

Chapter 4. Global Biomarker-Based Immunoassays Market: Sample Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Biomarker-Based Immunoassays Market Sample Movement Analysis
  • 4.3. Global Biomarker-Based Immunoassays Market Size & Trend Analysis, by sample, 2018 to 2030 (USD Million)
  • 4.4. Blood
    • 4.4.1. Blood market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.5. Tissue
    • 4.5.1. Tissue market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.6. Saliva
    • 4.6.1. Saliva market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.7. Urine
    • 4.7.1. Urine market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Global Biomarker-Based Immunoassays Market: Product Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Biomarker-Based Immunoassays Market Product Movement Analysis
  • 5.3. Global Biomarker-Based Immunoassays Market Size & Trend Analysis, by product, 2021 to 2033 (USD Million)
  • 5.4. Consumables
    • 5.4.1. Consumables market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.5. Instruments/Analyzers
    • 5.5.1. Instruments/Analyzers market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.6. Reagent & Kits
    • 5.6.1. Reagent & kits market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.7. Services
    • 5.7.1. Services market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Global Biomarker-Based Immunoassays Market: Biomarker Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Biomarker-Based Immunoassays Market Biomarker Movement Analysis
  • 6.3. Global Biomarker-Based Immunoassays Market Size & Trend Analysis, by biomarkers, 2021 to 2033 (USD Million)
  • 6.4. Safety & toxicity biomarkers
    • 6.4.1. Safety & toxicity biomarkers market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.5. Efficacy & Pharmacodynamic Biomarkers
    • 6.5.1. Efficacy & Pharmacodynamic Biomarkers market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.6. Predictive & Prognostic Biomarkers
    • 6.6.1. Predictive & prognostic biomarkers market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.7. Surrogate/Exploratory Biomarkers
    • 6.7.1. Surrogate/exploratory biomarkers market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Global Biomarker-Based Immunoassays Market: Diseases Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Global Biomarker-Based Immunoassays Market Diseases Movement Analysis
    • 7.2.1. Global Biomarker-Based Immunoassays Market Size & Trend Analysis, by diseases, 2021 to 2033 (USD Million)
  • 7.3. Cancer
    • 7.3.1. Cancer market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4. Cardiovascular Diseases
    • 7.4.1. Cardiovascular diseases market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5. Neurological Diseases
    • 7.5.1. Neurological diseases market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6. Immunological Diseases
    • 7.6.1. Immunological diseases testing market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7. Others
    • 7.7.1. Others market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Global Biomarker-Based Immunoassays Market: End Use Estimates & Trend Analysis

  • 8.1. Segment Dashboard
  • 8.2. Global Biomarker-Based Immunoassays Market End Use Movement Analysis
    • 8.2.1. Global Biomarker-Based Immunoassays Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
  • 8.3. Hospitals & Clinics
    • 8.3.1. Hospitals and clinics market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4. Diagnostic Laboratories
    • 8.4.1. Diagnostic Laboratories market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5. Research & Academic Institutes
    • 8.5.1. Research & Academic Institutes market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6. Others
    • 8.6.1. Others market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 9. Biomarker-Based Immunoassays Market: Regional Estimates & Trend Analysis

  • 9.1. Regional Dashboard
  • 9.2. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
  • 9.3. North America
    • 9.3.1. U.S.
      • 9.3.1.1. Key country dynamics
      • 9.3.1.2. Regulatory framework/ reimbursement structure
      • 9.3.1.3. Competitive scenario
      • 9.3.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.3.2. Canada
      • 9.3.2.1. Key country dynamics
      • 9.3.2.2. Regulatory framework/ reimbursement structure
      • 9.3.2.3. Competitive scenario
      • 9.3.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.3.3. Mexico
      • 9.3.3.1. Key country dynamics
      • 9.3.3.2. Regulatory framework/ reimbursement structure
      • 9.3.3.3. Competitive scenario
      • 9.3.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.4. Europe
    • 9.4.1. UK
      • 9.4.1.1. Key country dynamics
      • 9.4.1.2. Regulatory framework/ reimbursement structure
      • 9.4.1.3. Competitive scenario
      • 9.4.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.4.2. Germany
      • 9.4.2.1. Key country dynamics
      • 9.4.2.2. Regulatory framework/ reimbursement structure
      • 9.4.2.3. Competitive scenario
      • 9.4.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.4.3. France
      • 9.4.3.1. Key country dynamics
      • 9.4.3.2. Regulatory framework/ reimbursement structure
      • 9.4.3.3. Competitive scenario
      • 9.4.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.4.4. Italy
      • 9.4.4.1. Key country dynamics
      • 9.4.4.2. Regulatory framework/ reimbursement structure
      • 9.4.4.3. Competitive scenario
      • 9.4.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.4.5. Spain
      • 9.4.5.1. Key country dynamics
      • 9.4.5.2. Regulatory framework/ reimbursement structure
      • 9.4.5.3. Competitive scenario
      • 9.4.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.4.6. Norway
      • 9.4.6.1. Key country dynamics
      • 9.4.6.2. Regulatory framework/ reimbursement structure
      • 9.4.6.3. Competitive scenario
      • 9.4.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.4.7. Sweden
      • 9.4.7.1. Key country dynamics
      • 9.4.7.2. Regulatory framework/ reimbursement structure
      • 9.4.7.3. Competitive scenario
      • 9.4.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.4.8. Denmark
      • 9.4.8.1. Key country dynamics
      • 9.4.8.2. Regulatory framework/ reimbursement structure
      • 9.4.8.3. Competitive scenario
      • 9.4.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.5. Asia Pacific
    • 9.5.1. Japan
      • 9.5.1.1. Key country dynamics
      • 9.5.1.2. Regulatory framework/ reimbursement structure
      • 9.5.1.3. Competitive scenario
      • 9.5.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.5.2. China
      • 9.5.2.1. Key country dynamics
      • 9.5.2.2. Regulatory framework/ reimbursement structure
      • 9.5.2.3. Competitive scenario
      • 9.5.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.5.3. India
      • 9.5.3.1. Key country dynamics
      • 9.5.3.2. Regulatory framework/ reimbursement structure
      • 9.5.3.3. Competitive scenario
      • 9.5.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.5.4. Australia
      • 9.5.4.1. Key country dynamics
      • 9.5.4.2. Regulatory framework/ reimbursement structure
      • 9.5.4.3. Competitive scenario
      • 9.5.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.5.5. South Korea
      • 9.5.5.1. Key country dynamics
      • 9.5.5.2. Regulatory framework/ reimbursement structure
      • 9.5.5.3. Competitive scenario
      • 9.5.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.5.6. Thailand
      • 9.5.6.1. Key country dynamics
      • 9.5.6.2. Regulatory framework/ reimbursement structure
      • 9.5.6.3. Competitive scenario
      • 9.5.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.6. Latin America
    • 9.6.1. Brazil
      • 9.6.1.1. Key country dynamics
      • 9.6.1.2. Regulatory framework/ reimbursement structure
      • 9.6.1.3. Competitive scenario
      • 9.6.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.6.2. Argentina
      • 9.6.2.1. Key country dynamics
      • 9.6.2.2. Regulatory framework/ reimbursement structure
      • 9.6.2.3. Competitive scenario
      • 9.6.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.7. MEA
    • 9.7.1. South Africa
      • 9.7.1.1. Key country dynamics
      • 9.7.1.2. Regulatory framework/ reimbursement structure
      • 9.7.1.3. Competitive scenario
      • 9.7.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.7.2. Saudi Arabia
      • 9.7.2.1. Key country dynamics
      • 9.7.2.2. Regulatory framework/ reimbursement structure
      • 9.7.2.3. Competitive scenario
      • 9.7.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.7.3. UAE
      • 9.7.3.1. Key country dynamics
      • 9.7.3.2. Regulatory framework/ reimbursement structure
      • 9.7.3.3. Competitive scenario
      • 9.7.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.7.4. Kuwait
      • 9.7.4.1. Key country dynamics
      • 9.7.4.2. Regulatory framework/ reimbursement structure
      • 9.7.4.3. Competitive scenario
      • 9.7.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 10. Competitive Landscape

  • 10.1. Company/Competition Categorization
  • 10.2. Strategy Mapping
  • 10.3. Company Market Share Analysis, 2024
  • 10.4. List of Key Certification Providers/Scheme Owners
  • 10.5. Company Profiles/Listing
    • 10.5.1. F. Hoffmann-La Roche AG
      • 10.5.1.1. Company overview
      • 10.5.1.2. Financial performance
      • 10.5.1.3. Product benchmarking
      • 10.5.1.4. Strategic initiatives
    • 10.5.2. Abbott
      • 10.5.2.1. Company overview
      • 10.5.2.2. Financial performance
      • 10.5.2.3. Product benchmarking
      • 10.5.2.4. Strategic initiatives
    • 10.5.3. Thermo Fisher Scientific Inc
      • 10.5.3.1. Company overview
      • 10.5.3.2. Financial performance
      • 10.5.3.3. Product benchmarking
      • 10.5.3.4. Strategic initiatives
    • 10.5.4. Eurofins Scientific
      • 10.5.4.1. Company overview
      • 10.5.4.2. Financial performance
      • 10.5.4.3. Product benchmarking
      • 10.5.4.4. Strategic initiatives
    • 10.5.5. QIAGEN
      • 10.5.5.1. Company overview
      • 10.5.5.2. Financial performance
      • 10.5.5.3. Product benchmarking
      • 10.5.5.4. Strategic initiatives
    • 10.5.6. Bio-Rad Laboratories, Inc.
      • 10.5.6.1. Company overview
      • 10.5.6.2. Financial performance
      • 10.5.6.3. Product benchmarking
      • 10.5.6.4. Strategic initiatives
    • 10.5.7. Siemens Healthineers AG
      • 10.5.7.1. Company overview
      • 10.5.7.2. Financial performance
      • 10.5.7.3. Product benchmarking
      • 10.5.7.4. Strategic initiatives
    • 10.5.8. Merck KGaA
      • 10.5.8.1. Company overview
      • 10.5.8.2. Financial performance
      • 10.5.8.3. Product benchmarking
      • 10.5.8.4. Strategic initiatives
    • 10.5.9. PerkinElmer Inc.
      • 10.5.9.1. Company overview
      • 10.5.9.2. Financial performance
      • 10.5.9.3. Product benchmarking
      • 10.5.9.4. Strategic initiatives
    • 10.5.10. Agilent Technologies, Inc.
      • 10.5.10.1. Company overview
      • 10.5.10.2. Financial performance
      • 10.5.10.3. Product benchmarking
      • 10.5.10.4. Strategic initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviation
  • Table 3 U.S. biomarker-based immunoassays market, by sample, 2021 - 2033 (USD Million)
  • Table 4 U.S. biomarker-based immunoassays market, by product, 2021 - 2033 (USD Million)
  • Table 5 U.S. biomarker-based immunoassays market, by biomarkers, 2021 - 2033 (USD Million)
  • Table 6 U.S. biomarker-based immunoassays market, by diseases, 2021 - 2033 (USD Million)
  • Table 7 U.S. biomarker-based immunoassays market, by end use, 2021 - 2033 (USD Million)
  • Table 8 North America biomarker-based immunoassays market, by region, 2021 - 2033 (USD Million)
  • Table 9 North America biomarker-based immunoassays market, by sample, 2021 - 2033 (USD Million)
  • Table 10 North America biomarker-based immunoassays market, by product, 2021 - 2033 (USD Million)
  • Table 11 North America biomarker-based immunoassays market, by biomarkers, 2021 - 2033 (USD Million)
  • Table 12 North America biomarker-based immunoassays market, by diseases, 2021 - 2033 (USD Million)
  • Table 13 North America biomarker-based immunoassays market, by end use, 2021 - 2033 (USD Million)
  • Table 14 Canada biomarker-based immunoassays market, by sample, 2021 - 2033 (USD Million)
  • Table 15 Canada biomarker-based immunoassays market, by product, 2021 - 2033 (USD Million)
  • Table 16 Canada biomarker-based immunoassays market, by biomarkers, 2021 - 2033 (USD Million)
  • Table 17 Canada biomarker-based immunoassays market, by diseases, 2021 - 2033 (USD Million)
  • Table 18 Canada biomarker-based immunoassays market, by end use, 2021 - 2033 (USD Million)
  • Table 19 Mexico biomarker-based immunoassays market, by sample, 2021 - 2033 (USD Million)
  • Table 20 Mexico biomarker-based immunoassays market, by product, 2021 - 2033 (USD Million)
  • Table 21 Mexico biomarker-based immunoassays market, by biomarkers, 2021 - 2033 (USD Million)
  • Table 22 Mexico biomarker-based immunoassays market, by diseases, 2021 - 2033 (USD Million)
  • Table 23 Mexico biomarker-based immunoassays market, by end use, 2021 - 2033 (USD Million)
  • Table 24 Europe biomarker-based immunoassays market, by region, 2021 - 2033 (USD Million)
  • Table 25 Europe biomarker-based immunoassays market, by sample, 2021 - 2033 (USD Million)
  • Table 26 Europe biomarker-based immunoassays market, by product, 2021 - 2033 (USD Million)
  • Table 27 Europe biomarker-based immunoassays market, by biomarkers, 2021 - 2033 (USD Million)
  • Table 28 Europe biomarker-based immunoassays market, by diseases, 2021 - 2033 (USD Million)
  • Table 29 Europe biomarker-based immunoassays market, by end use, 2021 - 2033 (USD Million)
  • Table 30 UK biomarker-based immunoassays market, by sample, 2021 - 2033 (USD Million)
  • Table 31 UK biomarker-based immunoassays market, by product, 2021 - 2033 (USD Million)
  • Table 32 UK biomarker-based immunoassays market, by biomarkers, 2021 - 2033 (USD Million)
  • Table 33 UK biomarker-based immunoassays market, by diseases, 2021 - 2033 (USD Million)
  • Table 34 UK biomarker-based immunoassays market, by end use, 2021 - 2033 (USD Million)
  • Table 35 Germany biomarker-based immunoassays market, by sample, 2021 - 2033 (USD Million)
  • Table 36 Germany biomarker-based immunoassays market, by product, 2021 - 2033 (USD Million)
  • Table 37 Germany biomarker-based immunoassays market, by biomarkers, 2021 - 2033 (USD Million)
  • Table 38 Germany biomarker-based immunoassays market, by diseases, 2021 - 2033 (USD Million)
  • Table 39 Germany biomarker-based immunoassays market, by end use, 2021 - 2033 (USD Million)
  • Table 40 France biomarker-based immunoassays market, by sample, 2021 - 2033 (USD Million)
  • Table 41 France biomarker-based immunoassays market, by product, 2021 - 2033 (USD Million)
  • Table 42 France biomarker-based immunoassays market, by biomarkers, 2021 - 2033 (USD Million)
  • Table 43 France biomarker-based immunoassays market, by diseases, 2021 - 2033 (USD Million)
  • Table 44 France biomarker-based immunoassays market, by end use, 2021 - 2033 (USD Million)
  • Table 45 Italy biomarker-based immunoassays market, by sample, 2021 - 2033 (USD Million)
  • Table 46 Italy biomarker-based immunoassays market, by product, 2021 - 2033 (USD Million)
  • Table 47 Italy biomarker-based immunoassays market, by biomarkers, 2021 - 2033 (USD Million)
  • Table 48 Italy biomarker-based immunoassays market, by diseases, 2021 - 2033 (USD Million)
  • Table 49 Italy biomarker-based immunoassays market, by end use, 2021 - 2033 (USD Million)
  • Table 50 Spain biomarker-based immunoassays market, by sample, 2021 - 2033 (USD Million)
  • Table 51 Spain biomarker-based immunoassays market, by product, 2021 - 2033 (USD Million)
  • Table 52 Spain biomarker-based immunoassays market, by biomarkers, 2021 - 2033 (USD Million)
  • Table 53 Spain biomarker-based immunoassays market, by diseases, 2021 - 2033 (USD Million)
  • Table 54 Spain biomarker-based immunoassays market, by end use, 2021 - 2033 (USD Million)
  • Table 55 Denmark biomarker-based immunoassays market, by sample, 2021 - 2033 (USD Million)
  • Table 56 Denmark biomarker-based immunoassays market, by product, 2021 - 2033 (USD Million)
  • Table 57 Denmark biomarker-based immunoassays market, by biomarkers, 2021 - 2033 (USD Million)
  • Table 58 Denmark biomarker-based immunoassays market, by diseases, 2021 - 2033 (USD Million)
  • Table 59 Denmark biomarker-based immunoassays market, by end use, 2021 - 2033 (USD Million)
  • Table 60 Sweden biomarker-based immunoassays market, by sample, 2021 - 2033 (USD Million)
  • Table 61 Sweden biomarker-based immunoassays market, by product, 2021 - 2033 (USD Million)
  • Table 62 Sweden biomarker-based immunoassays market, by biomarkers, 2021 - 2033 (USD Million)
  • Table 63 Sweden biomarker-based immunoassays market, by diseases, 2021 - 2033 (USD Million)
  • Table 64 Sweden biomarker-based immunoassays market, by end use, 2021 - 2033 (USD Million)
  • Table 65 Norway biomarker-based immunoassays market, by sample, 2021 - 2033 (USD Million)
  • Table 66 Norway biomarker-based immunoassays market, by product, 2021 - 2033 (USD Million)
  • Table 67 Norway biomarker-based immunoassays market, by biomarkers, 2021 - 2033 (USD Million)
  • Table 68 Norway biomarker-based immunoassays market, by diseases, 2021 - 2033 (USD Million)
  • Table 69 Norway biomarker-based immunoassays market, by end use, 2021 - 2033 (USD Million)
  • Table 70 Asia Pacific biomarker-based immunoassays market, by region, 2021 - 2033 (USD Million)
  • Table 71 Asia Pacific biomarker-based immunoassays market, by sample, 2021 - 2033 (USD Million)
  • Table 72 Asia Pacific biomarker-based immunoassays market, by product, 2021 - 2033 (USD Million)
  • Table 73 Asia Pacific biomarker-based immunoassays market, by biomarkers, 2021 - 2033 (USD Million)
  • Table 74 Asia Pacific biomarker-based immunoassays market, by diseases, 2021 - 2033 (USD Million)
  • Table 75 Asia Pacific biomarker-based immunoassays market, by end use, 2021 - 2033 (USD Million)
  • Table 76 Japan biomarker-based immunoassays market, by sample, 2021 - 2033 (USD Million)
  • Table 77 Japan biomarker-based immunoassays market, by product, 2021 - 2033 (USD Million)
  • Table 78 Japan biomarker-based immunoassays market, by biomarkers, 2021 - 2033 (USD Million)
  • Table 79 Japan biomarker-based immunoassays market, by diseases, 2021 - 2033 (USD Million)
  • Table 80 Japan biomarker-based immunoassays market, by end use, 2021 - 2033 (USD Million)
  • Table 81 China biomarker-based immunoassays market, by sample, 2021 - 2033 (USD Million)
  • Table 82 China biomarker-based immunoassays market, by product, 2021 - 2033 (USD Million)
  • Table 83 China biomarker-based immunoassays market, by biomarkers, 2021 - 2033 (USD Million)
  • Table 84 China biomarker-based immunoassays market, by diseases, 2021 - 2033 (USD Million)
  • Table 85 China biomarker-based immunoassays market, by end use, 2021 - 2033 (USD Million)
  • Table 86 India biomarker-based immunoassays market, by sample, 2021 - 2033 (USD Million)
  • Table 87 India biomarker-based immunoassays market, by product, 2021 - 2033 (USD Million)
  • Table 88 India biomarker-based immunoassays market, by biomarkers, 2021 - 2033 (USD Million)
  • Table 89 India biomarker-based immunoassays market, by diseases, 2021 - 2033 (USD Million)
  • Table 90 India biomarker-based immunoassays market, by end use, 2021 - 2033 (USD Million)
  • Table 91 Australia biomarker-based immunoassays market, by sample, 2021 - 2033 (USD Million)
  • Table 92 Australia biomarker-based immunoassays market, by product, 2021 - 2033 (USD Million)
  • Table 93 Australia biomarker-based immunoassays market, by biomarkers, 2021 - 2033 (USD Million)
  • Table 94 Australia biomarker-based immunoassays market, by diseases, 2021 - 2033 (USD Million)
  • Table 95 Australia biomarker-based immunoassays market, by end use, 2021 - 2033 (USD Million)
  • Table 96 South Korea biomarker-based immunoassays market, by sample, 2021 - 2033 (USD Million)
  • Table 97 South Korea biomarker-based immunoassays market, by product, 2021 - 2033 (USD Million)
  • Table 98 South Korea biomarker-based immunoassays market, by biomarkers, 2021 - 2033 (USD Million)
  • Table 99 South Korea biomarker-based immunoassays market, by diseases, 2021 - 2033 (USD Million)
  • Table 100 South Korea biomarker-based immunoassays market, by end use, 2021 - 2033 (USD Million)
  • Table 101 Thailand biomarker-based immunoassays market, by sample, 2021 - 2033 (USD Million)
  • Table 102 Thailand biomarker-based immunoassays market, by product, 2021 - 2033 (USD Million)
  • Table 103 Thailand biomarker-based immunoassays market, by biomarkers, 2021 - 2033 (USD Million)
  • Table 104 Thailand biomarker-based immunoassays market, by diseases, 2021 - 2033 (USD Million)
  • Table 105 Thailand biomarker-based immunoassays market, by end use, 2021 - 2033 (USD Million)
  • Table 106 Latin America biomarker-based immunoassays market, by region, 2021 - 2033 (USD Million)
  • Table 107 Latin America biomarker-based immunoassays market, by sample, 2021 - 2033 (USD Million)
  • Table 108 Latin America biomarker-based immunoassays market, by product, 2021 - 2033 (USD Million)
  • Table 109 Latin America biomarker-based immunoassays market, by biomarkers, 2021 - 2033 (USD Million)
  • Table 110 Latin America biomarker-based immunoassays market, by diseases, 2021 - 2033 (USD Million)
  • Table 111 Latin America biomarker-based immunoassays market, by end use, 2021 - 2033 (USD Million)
  • Table 112 Brazil biomarker-based immunoassays market, by sample, 2021 - 2033 (USD Million)
  • Table 113 Brazil biomarker-based immunoassays market, by product, 2021 - 2033 (USD Million)
  • Table 114 Brazil biomarker-based immunoassays market, by biomarkers, 2021 - 2033 (USD Million)
  • Table 115 Brazil biomarker-based immunoassays market, by diseases, 2021 - 2033 (USD Million)
  • Table 116 Brazil biomarker-based immunoassays market, by end use, 2021 - 2033 (USD Million)
  • Table 117 Argentina biomarker-based immunoassays market, by sample, 2021 - 2033 (USD Million)
  • Table 118 Argentina biomarker-based immunoassays market, by product, 2021 - 2033 (USD Million)
  • Table 119 Argentina biomarker-based immunoassays market, by biomarkers, 2021 - 2033 (USD Million)
  • Table 120 Argentina biomarker-based immunoassays market, by diseases, 2021 - 2033 (USD Million)
  • Table 121 Argentina biomarker-based immunoassays market, by end use, 2021 - 2033 (USD Million)
  • Table 122 MEA biomarker-based immunoassays market, by region, 2021 - 2033 (USD Million)
  • Table 123 MEA biomarker-based immunoassays market, by sample, 2021 - 2033 (USD Million)
  • Table 124 MEA biomarker-based immunoassays market, by product, 2021 - 2033 (USD Million)
  • Table 125 MEA biomarker-based immunoassays market, by biomarkers, 2021 - 2033 (USD Million)
  • Table 126 MEA biomarker-based immunoassays market, by diseases, 2021 - 2033 (USD Million)
  • Table 127 MEA biomarker-based immunoassays market, by end use, 2021 - 2033 (USD Million)
  • Table 128 South Africa biomarker-based immunoassays market, by sample, 2021 - 2033 (USD Million)
  • Table 129 South Africa biomarker-based immunoassays market, by product, 2021 - 2033 (USD Million)
  • Table 130 South Africa biomarker-based immunoassays market, by biomarkers, 2021 - 2033 (USD Million)
  • Table 131 South Africa biomarker-based immunoassays market, by diseases, 2021 - 2033 (USD Million)
  • Table 132 South Africa biomarker-based immunoassays market, by end use, 2021 - 2033 (USD Million)
  • Table 133 Saudi Arabia biomarker-based immunoassays market, by sample, 2021 - 2033 (USD Million)
  • Table 134 Saudi Arabia biomarker-based immunoassays market, by product, 2021 - 2033 (USD Million)
  • Table 135 Saudi Arabia biomarker-based immunoassays market, by biomarkers, 2021 - 2033 (USD Million)
  • Table 136 Saudi Arabia biomarker-based immunoassays market, by diseases, 2021 - 2033 (USD Million)
  • Table 137 Saudi Arabia biomarker-based immunoassays market, by end use, 2021 - 2033 (USD Million)
  • Table 138 UAE biomarker-based immunoassays market, by sample, 2021 - 2033 (USD Million)
  • Table 139 UAE biomarker-based immunoassays market, by product, 2021 - 2033 (USD Million)
  • Table 140 UAE biomarker-based immunoassays market, by biomarkers, 2021 - 2033 (USD Million)
  • Table 141 UAE biomarker-based immunoassays market, by diseases, 2021 - 2033 (USD Million)
  • Table 142 global biomarker-based immunoassays market, by end use, 2021 - 2033 (USD Million)
  • Table 143 Kuwait biomarker-based immunoassays market, by sample, 2021 - 2033 (USD Million)
  • Table 144 Kuwait biomarker-based immunoassays market, by product, 2021 - 2033 (USD Million)
  • Table 145 Kuwait biomarker-based immunoassays market, by biomarkers, 2021 - 2033 (USD Million)
  • Table 146 Kuwait biomarker-based immunoassays market, by diseases, 2021 - 2033 (USD Million)
  • Table 147 Kuwait biomarker-based immunoassays market, by end use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Global biomarker-based immunoassays market segmentation
  • Fig. 2 Data analysis biomarkers
  • Fig. 3 Market formulation and validation
  • Fig. 4 Data validating & publishing
  • Fig. 5 Market research process
  • Fig. 6 Information procurement
  • Fig. 7 Primary research
  • Fig. 8 Value-chain-based sizing & forecasting
  • Fig. 9 QFD biomarker modelling for market share assessment
  • Fig. 10 Market formulation & validation
  • Fig. 11 Commodity flow analysis
  • Fig. 12 Market outlook
  • Fig. 13 Segment snapshot-1
  • Fig. 14 Segment snapshot-2
  • Fig. 15 Competitive landscape snapshot
  • Fig. 16 Market trends & outlook
  • Fig. 17 Porter's five force analysis
  • Fig. 18 PESTEL analysis
  • Fig. 19 Global biomarker-based immunoassays market: Sample outlook key takeaways
  • Fig. 20 Global biomarker-based immunoassays market: Sample movement analysis
  • Fig. 21 Blood market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 22 Tissue market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 23 Saliva market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 24 Urine market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 25 Global biomarker-based immunoassays market: Product outlook key takeaways
  • Fig. 26 Global biomarker-based immunoassays market: Product movement analysis
  • Fig. 27 Consumables market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 28 Instruments/Analyzers market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 29 Reagent & kits market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 30 Services market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 31 Global biomarker-based immunoassays market: Biomarker outlook key takeaways
  • Fig. 32 Global biomarker-based immunoassays market: Biomarker movement analysis
  • Fig. 33 Safety & toxicity biomarkers market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 34 Efficacy & pharmacodynamic biomarkers market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 35 Predictive & prognostic biomarkers market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 36 Surrogate/Exploratory biomarkers estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 37 Global biomarker-based immunoassays market: Biomarker outlook key takeaways
  • Fig. 38 Global biomarker-based immunoassays market: Biomarker movement analysis
  • Fig. 39 Cancer market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 40 Cardiovascular diseases market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 41 Neurological diseases market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 42 Immunological diseases market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 43 OtherOthers market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 44 Global biomarker-based immunoassays market: End Use outlook key takeaways
  • Fig. 45 Global biomarker-based immunoassays market: End Use movement analysis
  • Fig. 46 Hospitals and clinics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 47 Diagnostic laboratories market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 48 Research & academic institutes market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 49 Others estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 50 Biomarker-based immunoassays market: Regional outlook and key takeaways
  • Fig. 51 Regional outlook, 2024 & 2030
  • Fig. 52 North America
  • Fig. 53 North America market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 54 U.S. key country dynamics
  • Fig. 55 U.S. market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 56 Canada key country dynamics
  • Fig. 57 Canada market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 58 Europe
  • Fig. 59 Europe market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 60 UK key country dynamics
  • Fig. 61 UK market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 62 Germany
  • Fig. 63 Germany market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 64 France key country dynamics
  • Fig. 65 France market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 66 Italy key country dynamics
  • Fig. 67 Italy market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 68 Spain key country dynamics
  • Fig. 69 Spain market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 70 Denmark key country dynamics
  • Fig. 71 Denmark market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 72 Sweden key country dynamics
  • Fig. 73 Sweden market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 74 Norway key country dynamics
  • Fig. 75 Norway market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 76 Asia-Pacific
  • Fig. 77 Asia-Pacific market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 78 Japan key country dynamics
  • Fig. 79 Japan market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 80 China key country dynamics
  • Fig. 81 China market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 82 India key country dynamics
  • Fig. 83 India market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 84 South Korea key country dynamics
  • Fig. 85 South Korea market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 86 Australia key country dynamics
  • Fig. 87 Australia market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 88 Thailand key country dynamics
  • Fig. 89 Thailand market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 90 Latin America
  • Fig. 91 Latin America market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 92 Brazil key country dynamics
  • Fig. 93 Brazil market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 94 Mexico key country dynamics
  • Fig. 95 Mexico market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 96 Argentina key country dynamics
  • Fig. 97 Argentina market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 98 Middle East & Africa
  • Fig. 99 MEA market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 100 South Africa key country dynamics
  • Fig. 101 South Africa market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 102 Saudi Arabia key country dynamics
  • Fig. 103 Saudi Arabia market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 104 UAE key country dynamics
  • Fig. 105 UAE market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 106 Kuwait key country dynamics
  • Fig. 107 Kuwait market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 108 Market differentiators
  • Fig. 109 Key company market share analysis, 2024